Insights / Blog / Decentralized Trials
Clinion is supporting researchers in their fight against the Covid-19 pandemic.
- Summary
Summary
The Clinion EDC platform is being offered to researchers at a discounted price in their fight against the Covid-19 virus. As of May 15, Clinion is already supporting multiple Covid-19 studies.
We have developed a mobile Electronic Clinical Outcome Assessment (eCOA) application within a span of 2 weeks to manage decentralized patient participation and remote monitoring of subjects.
The mobile platform takes care patient enrolment, eConsent and Symptom tracking. The mobile application is integrated with Clinion’s Electronic Data Capture (EDC) system. Investigators and study personnel can monitor patients in real-time and reach out to them proactively.
Clinion EDC and eCOA mobile platform is available for researchers around the world for rapidly configuring and deploying Covid-19 studies.
A marketing leader with a sharp focus on strategic clarity, positioning, and GTM alignment. At Clinion, he drives marketing initiatives that connect narrative precision with measurable growth, ensuring the company’s AI-powered innovations resonate deeply across the life sciences industry.
Unlock the Future of Clinical Trials with Clinion.
Cut your trial costs by 35% and accelerate your time-to-market by 30%
Compliance
Fully Compliant with Global Standards
